PDE8 regulates rapid teff cell adhesion and proliferation independent of ICER

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Vang, Amanda G ^a   Ben Sasson, Shlomo Z ^b   Dong, Hongli ^a   Kream, Barbara ^a   de Ninno, Michael P ^c   Claffey, Michelle M ^c   Housley, William ^a   Clark, Robert B ^a   Epstein, Paul M ^a   Brocke, Stefan ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CLAUDIN 5; CYCLIC AMP; CYCLIC AMP EARLY REPRESSOR PROTEIN; CYTOKINE; DIPYRIDAMOLE; GLYCOPROTEIN; INTEGRIN; PF 4957325 00; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE VIII; REPRESSOR PROTEIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULAR ADHESION MOLECULE; CLDN5 PROTEIN, MOUSE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; MEMBRANE PROTEIN; PDE4B PROTEIN, MOUSE; PDE8A PROTEIN, MOUSE; PHOSPHODIESTERASE IV;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; LYMPHOCYTE PROLIFERATION; MICROVASCULATURE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HYDROLYSIS; INTRACELLULAR SPACE; METABOLISM; T LYMPHOCYTE; TH1 CELL; TIGHT JUNCTION; TIME; VASCULAR ENDOTHELIUM;

ERAGROSTIS TEF; MUS;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL PROLIFERATION; CHEMOKINE CXCL12; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DIPYRIDAMOLE; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROLYSIS; INTRACELLULAR SPACE; MEMBRANE PROTEINS; MICE; PHOSPHODIESTERASE INHIBITORS; T-LYMPHOCYTES; TH1 CELLS; TIGHT JUNCTIONS; TIME FACTORS;

EID: 77957883715     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012011     Document Type: Article

References (72)

1. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
2. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
3. Schillace RV, Carr DW (2006) The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions. Crit Rev Immunol 26: 113-131.
4. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118: 1945-1958.
5. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci U S A 98: 6319-6324.
6. Li L, Yee C, Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283: 848-851.
7. Jin S, Richter W, Conti M (2007) Insights into the Physiological Functions of PDE4 fromKnockout Mice. In: Beavo JA, Francis SH, HouslayMD, eds. Cyclic Nucleotide Phosphodiesterases in Health and Disease. New York, NY: CRC Press. pp 323-346.
8. Jung S, Zielasek J, Kollner G, Donhauser T, Toyka K, et al. (1996) Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 68: 1-11.
9. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C (2007) Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 178: 4820-4831.
10. Ekholm D, Hemmer B, Gao G, Vergelli M, Martin R, et al. (1997) Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J Immunol 159: 1520-1529.
11. Lerner A, Epstein PM (2006) Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393: 21-41.
12. Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, et al. (1974) Modulation of inflammation and immunity by cyclic AMP. Science 184: 19-28.
13. Baillie GS, Scott JD, Houslay MD (2005) Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579: 3264-3270.
14. Sitkovsky MV, Ohta A (2005) The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 26: 299-304.
15. Sitkovsky MV (2003) Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 65: 493-501.
16. Frohman EM, Monson NL, Lovett-Racke AE, Racke MK (2001) Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis. J Clin Immunol 21: 61-73.
17. Beavo J, Houslay M, Francis S (2007) Cyclic Nucleotide Phosphodiesterase Superfamily. In: Beavo JA, Francis SH, Houslay MD, eds. Cyclic Nucleotide Phosphodiesterases in Health and Disease. New York, NY: CRC Press. pp 3-18.
18. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
19. Sommer N, Martin R, McFarland HF, Quigley L, Cannella B, et al. (1997) Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol 79: 54-61.
20. Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, et al. (2006) Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)- 2-[4-(1,1,1,3,3,3-hexafluoro-2-hydrox ypropan-2-yl)-phenyl]-ethyl]-3- methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 319: 63-72.
21. Bielekova B, Richert N, Howard T, Packer AN, Blevins G, et al. (2009) Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult Scler 15: 1206-1214.
22. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
23. Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155: 288-290.
24. Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315.
25. Dong H, Osmanova V, Epstein PM, Brocke S (2006) Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem Biophys Res Commun 345: 713-719.
26. Shulman Z, Shinder V, Klein E, Grabovsky V, Yeger O, et al. (2009) Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin. Immunity 30: 384-396.
27. Cinamon G, Shinder V, Alon R (2001) Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2: 515-522.
28. Laudanna C, Campbell JJ, Butcher EC (1997) Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem 272: 24141-24144.
29. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL (2007) cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 27: 1014-1022.
30. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, et al. (2005) Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105: 3569-3576.
31. Sanz MJ, Cortijo J, Taha MA, Cerda-Nicolas M, Schatton E, et al. (2007) Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152: 481-492.
32. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, et al. (2009) IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 106: 7119-7124.
33. Bartolome RA, Sanz-Rodriguez F, Robledo MM, Hidalgo A, Teixido J (2003) Rapid up-regulation of alpha4 integrin-mediated leukocyte adhesion by transforming growth factor-beta1. Mol Biol Cell 14: 54-66.
34. Sullivan GW, Lee DD, Ross WG, DiVietro JA, Lappas CM, et al. (2004) Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol 75: 127-134.
35. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB (1998) Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246: 570-577.
36. Soderling SH, Bayuga SJ, Beavo JA (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci U S A 95: 8991-8996.
37. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314.
38. Steinman L (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510-518.
39. Thompson WJ, Ross CP, Hersh EM, Epstein PM, Strada SJ (1980) Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine. J Cyclic Nucleotide Res 6: 25-36.
40. Wunder F, Gnoth MJ, Geerts A, Barufe D (2009) A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors. Mol Pharm 6: 326-336.
41. Coeugniet E, Bendtzen K, Bendixen G (1976) Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin. Acta Med Scand 199: 99-104.
42. Kim HH, Liao JK (2008) Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol 28: s39-42.
43. Layseca-Espinosa E, Baranda L, Alvarado-Sanchez B, Portales-Perez D, Portillo-Salazar H, et al. (2003) Rolipram inhibits polarization and migration of human T lymphocytes. J Invest Dermatol 121: 81-87.
44. Goldfinger LE, Han J, Kiosses WB, Howe AK, Ginsberg MH (2003) Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration. J Cell Biol 162: 731-741.
45. Lim CJ, Han J, Yousefi N, Ma Y, Amieux PS, et al. (2007) Alpha4 integrins are type I cAMP-dependent protein kinase-anchoring proteins. Nat Cell Biol 9: 415-421.
46. Chilcoat CD, Sharief Y, Jones SL (2008) Tonic protein kinase A activity maintains inactive beta2 integrins in unstimulated neutrophils by reducing myosin light-chain phosphorylation: role of myosin light-chain kinase and Rho kinase. J Leukoc Biol 83: 964-971.
47. Bodor J, Bodorova J, Gress RE (2000) Suppression of T cell function: a potential role for transcriptional repressor ICER. J Leukoc Biol 67: 774-779.
48. Liu F, Lee SK, Adams DJ, Gronowicz GA, Kream BE (2007) CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment. Bone 40: 1135-1143.
49. Netherton SJ, Maurice DH (2005) Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67: 263-272.
50. Ashikaga T, Strada SJ, Thompson WJ (1997) Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells. Biochem Pharmacol 54: 1071-1079.
51. Gavard J, Gutkind JS (2008) VE-cadherin and claudin-5: it takes two to tango. Nat Cell Biol 10: 883-885.
52. Kinnecom K, Pachter JS (2005) Selective capture of endothelial and perivascular cells from brain microvessels using laser capture microdissection. Brain Res Brain Res Protoc 16: 1-9.
53. Beavo JA, Brunton LL (2002) Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718.
54. Price GM, Chrobak KM, Tien J (2008) Effect of cyclic AMP on barrier function of human lymphatic microvascular tubes. Microvasc Res 76: 46-51.
55. Weyrich AS, Denis MM, Kuhlmann-Eyre JR, Spencer ED, Dixon DA, et al. (2005) Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation 111: 633-642.
56. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333 (Pt 1): 139-149.
57. Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK (2006) Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol 99: 431-439.
58. Vasta V (2007) cAMP-Phosphodiesterase 8 Family. In: Beavo JA, Francis SH, Houslay MD, eds. Cyclic Nucleotide Phosphodiesterases in Health and Disease. New York, NY: CRC press. pp 205-219.
59. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, et al. (1997) Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 45: 132-139.
60. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, et al. (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161: 653-660.
61. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53.
62. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T (1999) Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 96: 6896-6901.
63. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348: 24-32.
64. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23.
65. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
66. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911-923.
67. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
68. Steinman L (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85: 299-302.
69. Ford ML, Onami TM, Sperling AI, Ahmed R, Evavold BD (2003) CD43 modulates severity and onset of experimental autoimmune encephalomyelitis. J Immunol 171: 6527-6533.
70. Li M, Ransohoff RM (2008) Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 84: 116-131.
71. Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622-2629.
72. Steinman L (2004) Immune therapy for autoimmune diseases. Science 305: 212-216.